Glucagon-like peptide-1 (GLP-1) is an incretin hormone best known for regulating blood glucose, but its effects extend beyond metabolism. GLP-1 receptors are found throughout the central nervous system, including regions that control appetite, cognition, and motor function. This distribution suggests that GLP-1 and its synthetic analogues—such as semaglutide and liraglutide—may influence brain processes including satiety signalling, neuroprotection, and possibly cognitive health. Whilst GLP-1 receptor agonists are licensed in the UK for type 2 diabetes and weight management, emerging research is exploring their potential neurological benefits, though definitive clinical evidence remains under investigation.

What Is GLP-1 and How Does It Work in the Body?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced primarily by specialised L-cells in the distal small intestine and colon. This naturally occurring peptide plays a crucial role in glucose homeostasis and metabolic regulation. When food enters the gastrointestinal tract, GLP-1 is released into the bloodstream in response to nutrient intake, particularly carbohydrates and fats.

The hormone exerts its effects by binding to GLP-1 receptors (GLP-1R), which are G-protein coupled receptors. In the pancreas, GLP-1 stimulates glucose-dependent insulin secretion from beta cells whilst simultaneously suppressing glucagon release from alpha cells. This dual action helps maintain blood glucose levels within the normal range, which is why GLP-1 receptor agonists have become important therapeutic agents for type 2 diabetes mellitus.

Naturally produced GLP-1 has a very short half-life of approximately two to three minutes, as it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). This brief duration of action prompted the development of synthetic GLP-1 receptor agonists—medications engineered to resist enzymatic breakdown and provide sustained therapeutic effects. Examples include semaglutide, liraglutide, dulaglutide, and exenatide, which are licensed in the UK for managing type 2 diabetes, with only semaglutide 2.4 mg (Wegovy®) and liraglutide 3 mg (Saxenda®) specifically licensed for weight management.

Importantly, GLP-1 receptors have been reported in various tissues beyond the pancreas, including the gastrointestinal system and, significantly, the central nervous system. This distribution suggests that GLP-1 may have physiological effects beyond glucose regulation, including potential actions within the brain that influence appetite, cognition, and possibly neuroprotection, though many of these effects remain under investigation.

Effects of GLP-1 on Appetite and Food Intake

One of the most clinically significant effects of GLP-1 on the brain relates to appetite regulation and satiety. GLP-1 receptors are abundantly expressed in key appetite-regulating regions of the central nervous system, particularly the hypothalamus and brainstem. These areas integrate hormonal and neural signals to control hunger, fullness, and energy balance.

When GLP-1 binds to receptors in the arcuate nucleus of the hypothalamus, it influences populations of neurons that regulate feeding behaviour. Specifically, GLP-1 activates pro-opiomelanocortin (POMC) neurons, which promote satiety, whilst inhibiting neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, which typically stimulate appetite. This dual modulation creates a powerful anorexigenic (appetite-suppressing) effect.

Additionally, GLP-1 acts on the area postrema and nucleus tractus solitarius in the brainstem—regions that lack a complete blood-brain barrier and can directly sense circulating hormones. Activation of GLP-1 receptors in these areas enhances feelings of fullness and reduces food intake. This mechanism explains why GLP-1 receptor agonists can be effective for weight management. In the UK, NICE Technology Appraisal 875 specifically recommends semaglutide 2.4 mg (Wegovy®) for adults with a BMI of at least 35 kg/m² (or 30 kg/m² with weight-related comorbidities) alongside a reduced-calorie diet and increased physical activity.

Clinically, patients prescribed GLP-1 receptor agonists for weight management commonly report:

• Reduced hunger between meals

• Earlier onset of satiety during eating

• Decreased food cravings, particularly for high-calorie foods

• Slower gastric emptying, which prolongs feelings of fullness

These appetite-related effects are generally dose-dependent and may be accompanied by gastrointestinal side effects including nausea, which typically improves with continued treatment. The slowing of gastric emptying may attenuate over time with longer-acting agents and can affect the absorption of some oral medicines. Patients should inform healthcare professionals about all medications they take and follow specific guidance regarding medication timing and perioperative fasting if they require surgery. For optimal results, these medications should be used alongside dietary modifications and increased physical activity, as recommended in NHS weight management pathways.

GLP-1's Role in Neuroprotection and Cognitive Function

Beyond metabolic and appetite regulation, emerging research suggests that GLP-1 may have neuroprotective properties that could influence brain health and cognitive function. GLP-1 receptors are expressed in various brain regions including the hippocampus, cortex, and substantia nigra—areas critical for memory, learning, and motor control.

Preclinical studies have demonstrated several potential neuroprotective mechanisms of GLP-1:

• Reduction of oxidative stress and inflammation: GLP-1 receptor activation appears to decrease neuroinflammatory markers and oxidative damage in experimental models, which are implicated in neurodegenerative conditions.

• Enhancement of neuronal survival: GLP-1 may promote neuronal growth and survival by activating intracellular signalling pathways that protect against apoptosis (programmed cell death).

• Improvement of synaptic plasticity: Some research indicates that GLP-1 can enhance long-term potentiation, a cellular mechanism underlying learning and memory formation.

• Modulation of amyloid and tau pathology: In animal models of Alzheimer's disease, GLP-1 receptor agonists have shown potential to reduce the accumulation of amyloid plaques and tau tangles, the hallmark pathological features of the condition.

Whilst these findings are promising, it is important to emphasise that most evidence comes from preclinical studies, and the translation to human neuroprotection remains under investigation. There is currently no official indication for GLP-1 receptor agonists in treating neurodegenerative diseases, and they should not be considered established neuroprotective therapies.

Some observational studies have suggested that people with type 2 diabetes treated with GLP-1 receptor agonists may have a lower risk of developing dementia compared to those on other glucose-lowering medications. However, these associations do not prove causation, and confounding factors such as better overall metabolic control may contribute to the observed benefits. Patients interested in cognitive health should focus on evidence-based strategies including cardiovascular risk management, physical activity, cognitive engagement, and adherence to medications for established conditions.

Clinical Evidence: GLP-1 Medications and Brain Health

The potential neurological effects of GLP-1 receptor agonists are being actively investigated in clinical trials, particularly regarding neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease. Several studies have explored whether these medications might offer therapeutic benefits beyond their established metabolic effects.

In Alzheimer's disease research, small clinical trials have examined GLP-1 receptor agonists including liraglutide and semaglutide. Some studies have reported modest improvements or stabilisation in cognitive assessments and brain glucose metabolism measured by PET imaging. However, these trials have generally been small, short-term, and exploratory in nature. Larger, definitive phase III trials are ongoing to determine whether GLP-1 receptor agonists can meaningfully slow cognitive decline or reduce Alzheimer's disease progression.

For Parkinson's disease, preliminary clinical evidence has investigated whether GLP-1 receptor agonists might slow motor symptom progression or provide neuroprotection to dopaminergic neurons. Early-phase trials with exenatide showed some encouraging signals, but subsequent larger studies have produced mixed results. The current evidence does not support routine use of GLP-1 receptor agonists for Parkinson's disease outside of research settings.

Regarding stroke and cerebrovascular disease, some observational data suggest that GLP-1 receptor agonists may be associated with reduced stroke risk in people with type 2 diabetes, possibly through improvements in cardiovascular risk factors such as blood pressure, weight, and glycaemic control. Some GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials, though specific product indications vary according to their UK SmPCs.

Important patient safety considerations include:

• GLP-1 receptor agonists are currently licensed only for type 2 diabetes and, for specific products, weight management—not for neurological conditions

• Common side effects include nausea, vomiting, diarrhoea, and constipation, which usually improve over time

• Patients should seek urgent medical help for symptoms suggestive of pancreatitis (severe, persistent abdominal pain, often radiating to the back, with or without vomiting)

• Gallbladder problems including gallstones and inflammation may occur

• Risk of hypoglycaemia is increased when used with insulin or sulfonylureas

• Diabetic retinopathy complications may occur with semaglutide, particularly with rapid improvement in blood glucose control

• Severe gastrointestinal side effects may lead to dehydration and acute kidney injury

• These medications are not recommended during pregnancy or breast-feeding

Patients should report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app).

Patients interested in the potential cognitive or neuroprotective effects of GLP-1 medications should discuss this with their GP or specialist, recognising that whilst research is promising, definitive clinical evidence for brain health benefits is still emerging. Current prescribing should follow NICE guidance for approved indications, with any neurological benefits considered potential additional effects rather than primary treatment goals.

Frequently Asked Questions